INTERIM REPORT JANUARY – MARCH 2006

• Turnover during the period amounted to SEK 282.2 (198.0) million, an increase of 43 percent. • Operating income amounted to SEK 56.0 (-0.2) million. • Net income after tax amounted to SEK 39.0 (3.5) million. • Earnings per share before dilution amounted to SEK 1.57 (0.14). • Continued very positive development of sales. • Registration application for DUROLANE submitted to FDA in USA.